JUPITER, Fla., Feb. 4, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors.
“Ms. Kampf will provide invaluable guidance as an Independent Member of Marizyme’s Board of Directors as the company accelerates clinical and commercial development and puts a concurrent emphasis on revenue generation in the year ahead,” said Dr. Neil J. Campbell, Marizyme’s CEO, President and Board Member. “She has a stellar reputation as a global business executive and thought leader in the life science arena.”
Ms. Kampf has more than 30 years’ experience as a global business executive and thought leader on talent and diversity in the life science industries and on not-for-profit Boards. She is currently CEO of JBK Associates International, a full-service executive talent solutions firm, with a specialty in life sciences, which she founded in 2003. Prior to founding JBK and moving into the life science industry, Ms. Kampf held positions of increasing responsibility that focused on product development, marketing, sales and organizational development.
Ms. Kampf has significant not-for-profit board and advisory committee experience, is deeply committed to enhancing the careers and well-being of other women and has won numerous awards. She was recognized as one of New Jersey’s Best 50 Women in Business, an Enterprising Woman of The Year, an Ernst & Young Entrepreneurial Winning Woman and a Brava Smart CEO Winner. In 2013 and 2009, Ms. Kampf was recognized as one of PharmaVoice’s 100 most inspiring people in the life science industry.
Ms. Kampf earned a BA in Political Science from the University of Rhode Island where she minored in Marketing.
Ms. Kampf commented, “I am excited to join Marizyme’s board and to support the company as it builds its promising suite of therapies that address unmet needs in diseases with high mortality and costs.”
About Marizyme, Inc.
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company’s flagship product, DuraGraft¬Æ, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase¬Æ platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.
This press release may contain certain forward-looking statements, including those relating to Marizyme’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified using forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company’s risk factor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Tiberend Strategic Advisors, Inc.
Miriam Weber Miller
SOURCE Marizyme, Inc.